Change search
ReferencesLink to record
Permanent link

Direct link
Use of 5α-reductase inhibitors for lower urinary tract symptoms and risk of prostate cancer in Swedish men: nationwide, population based case-control study
Umeå University, Faculty of Medicine, Department of Surgical and Perioperative Sciences, Urology and Andrology. Department of Urology, Ryhov County Hospital, 551 85 Jönköping, Sweden.
Show others and affiliations
2013 (English)In: BMJ (Clinical Research Edition), ISSN 0959-8138, Vol. 346, f3406Article in journal (Refereed) Published
Abstract [en]

OBJECTIVE: To assess the association between 5α-reductase inhibitor (5-ARI) use in men with lower urinary tract symptoms and prostate cancer risk.

DESIGN: Nationwide, population based case-control study for men diagnosed with prostate cancer in 2007-09 within the Prostate Cancer data Base Sweden 2.0.

SETTING: The National Prostate Cancer Register, National Patient Register, census, and Prescribed Drug Register in Sweden, from which we obtained data on 5-ARI use before date of prostate cancer diagnosis.

PARTICIPANTS: 26,735 cases and 133,671 matched controls; five controls per case were randomly selected from matched men in the background population. 7815 men (1499 cases and 6316 controls) had been exposed to 5-ARI. 412 men had been exposed to 5-ARI before the diagnosis of a cancer with Gleason score 8-10.

MAIN OUTCOME MEASURES: Risk of prostate cancer calculated as odds ratios and 95% confidence intervals by conditional logistic regression analyses.

RESULTS: Risk of prostate cancer overall decreased with an increasing duration of exposure; men on 5-ARI treatment for more than three years had an odds ratio of 0.72 (95% confidence interval 0.59 to 0.89; P<0.001 for trend). The same pattern was seen for cancers with Gleason scores 2-6 and score 7 (both P<0.001 for trend). By contrast, the risk of tumours with Gleason scores 8-10 did not decrease with increasing exposure time to 5-ARI (for 0-1 year of exposure, odds ratio 0.96 (95% confidence interval 0.83 to 1.11); for 1-2 years, 1.07 (0.88 to 1.31); for 2-3 years, 0.96 (0.72 to 1.27); for >3 years, 1.23 (0.90 to 1.68); P=0.46 for trend).

CONCLUSIONS: Men treated with 5-ARI for lower urinary tract symptoms had a decreased risk of cancer with Gleason scores 2-7, and showed no evidence of an increased risk of cancer with Gleason scores 8-10 after up to four years' treatment.

Place, publisher, year, edition, pages
2013. Vol. 346, f3406
National Category
Urology and Nephrology
URN: urn:nbn:se:umu:diva-107963DOI: 10.1136/bmj.f3406ISI: 000320941900004PubMedID: 23778271OAI: diva2:849894
Available from: 2015-08-31 Created: 2015-08-31 Last updated: 2016-09-12Bibliographically approved

Open Access in DiVA

fulltext(1145 kB)3 downloads
File information
File name FULLTEXT01.pdfFile size 1145 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Robinson, DavidStattin, Pär
By organisation
Urology and Andrology
In the same journal
BMJ (Clinical Research Edition)
Urology and Nephrology

Search outside of DiVA

GoogleGoogle Scholar
Total: 3 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 51 hits
ReferencesLink to record
Permanent link

Direct link